Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls

• Published in: European journal of nuclear medicine and molecular imaging Vol. 38; no. 9; pp. 1702 - 1714
• Main Authors: Barthel, Henryk, Luthardt, Julia, Becker, Georg, Patt, Marianne, Hammerstein, Eva, Hartwig, Kristin, Eggers, Birk, Sattler, Bernhard, Schildan, Andreas, Hesse, Swen, Meyer, Philipp M., Wolf, Henrike, Zimmermann, Torsten, Reischl, Joachim, Rohde, Beate, Gertz, Hermann-Josef, Reininger, Cornelia, Sabri, Osama
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.09.2011
• Subjects: Alzheimer Disease - diagnostic imaging; Alzheimer Disease - metabolism; Amyloid beta-Peptides - metabolism; Aniline Compounds - adverse effects; Aniline Compounds - metabolism; Biomarkers - metabolism; Brain - diagnostic imaging; Brain - metabolism; Cardiology; Case-Control Studies; Diagnosis, Differential; Feasibility Studies; Female; Humans; Image Processing, Computer-Assisted; Imaging; Kinetics; Male; Medicine; Medicine & Public Health; Middle Aged; Nuclear Medicine; Oncology; Original Article; Orthopedics; Positron-Emission Tomography - methods; Precision Medicine; Radiology; Safety; Stilbenes - adverse effects; Stilbenes - metabolism; β-Amyloid; Florbetaben; Alzheimer’s disease; PET

Purpose Complementing clinical findings with those generated by biomarkers—such as β-amyloid-targeted positron emission tomography (PET) imaging—has been proposed as a means of increasing overall accuracy in the diagnosis of Alzheimer’s disease (AD). Florbetaben ([ 18 F]BAY 94-9172) is a novel β-amy...